Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape
Small · 2025-07 · 21 (29)
DOI: 10.1002/smll.202502315 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Small, online erschienen am 02.06.2025. Verfasst von Nimeet Desai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Eye and Vision Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, L7 8TX, UK. Hauptthemen laut MEDLINE: Nanoparticles. Die Arbeit wurde bisher 329-mal zitiert (Crossref) und nennt 593 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Anusandhan National Research Foundation.
Abstract (Originalsprache)
Nanoparticle‐based therapeutics, emerging from advances in nanotechnology, outperform traditional drug therapies by virtue of their distinct biological properties that enhance therapeutic efficacy, reduce toxicity, and enable precise targeting. Since the 1980s, the number of nanoparticle‐based pharmaceutical products has expanded considerably, capturing a significant portion of the pharmaceutical market. These systems function as therapeutic agents or as vehicles for delivering active pharmaceutical or diagnostic compounds to targeted areas. However, despite their transformative potential, the development of comprehensive and harmonized regulatory frameworks for nanomedicines remains a critical challenge. This review provides a current overview of market‐approved nanoparticle therapeutics, analyzing global regulatory strategies, including pre‐clinical testing, safety assessments, manufacturing processes, and quality control standards. By discussing the existing shortcomings, this review highlights the importance of adaptive regulatory pathways in a global context. It aims to support researchers and stakeholders in navigating the regulatory landscape, facilitating the successful commercialization and clinical translation of nanoparticle‐based therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Eye and Vision Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, L7 8TX, UK.
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research-Ahmedabad (NIPER-A), Gandhinagar, Gujarat, 382355, India.
- Maliba Pharmacy College, Uka Tarsadia University, Surat, Gujarat, 394350, India.
- University Center of Excellence in Research, Baba Farid University of Health Sciences, Faridkot, Punjab, 151203, India.
- School of Biochemical Engineering, Indian Institute of Technology (BHU), Varanasi, Uttar Pradesh, 221005, India.
- School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, UK.
ORCID-Profile: Nimeet Desai, Lalitkumar K Vora
Förderung
- Anusandhan National Research Foundation
Zitieren
APA
Desai, N., Rana, D., Patel, M., Bajwa, N., Prasad, R., & Vora, L. K. (2025). Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape. Small, 21(29). https://doi.org/10.1002/smll.202502315
Vancouver
Desai N, Rana D, Patel M, Bajwa N, Prasad R, Vora LK. Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape. Small. 2025;21(29). doi:10.1002/smll.202502315
BibTeX
@article{Desai2025,
author = {Desai, Nimeet and Rana, Dhwani and Patel, Mitali and Bajwa, Neha and Prasad, Rajendra and Vora, Lalitkumar K},
title = {Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape},
journal = {Small},
year = {2025},
volume = {21},
number = {29},
doi = {10.1002/smll.202502315}
}
EUVIMED